Intersect ENT, Inc
XENT
XENT was delisted on the 12th of May, 2022.
112 hedge funds and large institutions have $460M invested in Intersect ENT, Inc in 2020 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 43 reducing their positions, and 13 closing their positions.
668% more call options, than puts
Call options by funds: $960K | Put options by funds: $125K
31% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 13
23% more capital invested
Capital invested by funds: $373M → $460M (+$87.3M)
4% more funds holding
Funds holding: 108 → 112 (+4)
21% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 43
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$19.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$18.8M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$13.5M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$7.8M |
| 5 |
Jennison Associates
New York
|
+$6.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$18.2M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$14.1M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$11M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$3.57M |
| 5 |
PVI
Pura Vida Investments
New York
|
-$2.96M |
XENT Hedge Fund Activity: Q3 2020 in Review
112 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Intersect ENT, Inc (XENT) for Q3 2020, worth a combined $460M — up 23% from $373M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new XENT positions and 13 closed out — a net gain of 4 holders — while 34 added to existing stakes and 43 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $19.9M. The largest seller was Deerfield Management, cutting an estimated $18.2M.
- 112 institutional investors held Intersect ENT, Inc (XENT) as of Q3 2020, up from 108 in Q2 2020.
- Funds reported $460M of Intersect ENT, Inc stock for Q3 2020, up 23% quarter-over-quarter.
- 17 funds opened new Intersect ENT, Inc positions in Q3 2020 and 13 closed out, a net change of +4 holders.
- The largest Intersect ENT, Inc buyer in Q3 2020 was Fidelity Investments, an estimated $19.9M added.
- The largest Intersect ENT, Inc seller in Q3 2020 was Deerfield Management, an estimated $18.2M sold.
Based on aggregated 13F filings for Q3 2020.